RARE - Ultragenyx reports serious adverse effects in gene therapy trial
2024-04-15 09:42:46 ET
Shares of Ultragenyx Pharmaceutical ( NASDAQ: RARE ) plunged as much as 7% on Monday after the company reported serious adverse effects in a gene therapy trial evaluating its investigational drug candidate, GTX-102, in patients with Angelman syndrome....
Ultragenyx reports serious adverse effects in gene therapy trial